Page last updated: 2024-12-09

(1-methylsulfonyl-4-piperidinyl)-(4-morpholinyl)methanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

(1-methylsulfonyl-4-piperidinyl)-(4-morpholinyl)methanone is a chemical compound with the molecular formula C11H20N2O4S. It is more commonly known as **(1-methylsulfonyl-4-piperidinyl)morpholine amide**, or simply **MSP**.

**Importance in Research:**

MSP is a potent and selective **agonist** of the **µ-opioid receptor**. This means it binds to and activates the µ-opioid receptor, which is a major target for pain relief, addiction, and other therapeutic applications.

Here's why MSP is important for research:

* **Understanding Opioid Pharmacology:** MSP has been used extensively in research to study the structure-activity relationships of µ-opioid receptor agonists and to develop new analgesics with improved efficacy and reduced side effects.
* **Drug Discovery:** MSP serves as a valuable lead compound for the development of novel opioid analgesics. Researchers can modify its structure to enhance its pharmacological properties, such as potency, selectivity, and bioavailability.
* **Addiction Research:** MSP can be used to investigate the mechanisms of opioid dependence and addiction. Its ability to activate the µ-opioid receptor allows researchers to study the cellular and molecular events involved in addiction.
* **Pain Management:** MSP has demonstrated analgesic activity in animal models of pain. Its potency and selectivity for the µ-opioid receptor make it a potential candidate for treating chronic pain conditions.

**However, it's important to note that MSP is a research tool and not currently approved for therapeutic use. Further studies are needed to evaluate its safety and efficacy in humans.**

**Other relevant information:**

* MSP is a white solid with a melting point of 150-152°C.
* It is soluble in methanol, ethanol, and chloroform.
* MSP is a chiral molecule, with two enantiomers (R-MSP and S-MSP) that exhibit different pharmacological profiles.

Overall, MSP is a valuable tool for research in the field of opioid pharmacology, drug discovery, and pain management. It provides insights into the mechanisms of opioid action and serves as a lead compound for the development of novel analgesics with improved therapeutic potential.

Cross-References

ID SourceID
PubMed CID647201
CHEMBL ID1509745
CHEBI ID116173

Synonyms (12)

Synonym
AKOS000439814
MLS000034203
smr000013611
(1-methanesulfonyl-piperidin-4-yl)-morpholin-4-yl-methanone
CHEBI:116173
(1-methylsulfonylpiperidin-4-yl)-morpholin-4-ylmethanone
[1-(methylsulfonyl)piperidin-4-yl](morpholin-4-yl)methanone
STK891652
HMS2340N23
CHEMBL1509745
Q27198905
(1-methylsulfonyl-4-piperidinyl)-(4-morpholinyl)methanone
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperidinecarboxamide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency16.36010.004110.890331.5287AID504467
thyroid stimulating hormone receptorHomo sapiens (human)Potency1.00000.001318.074339.8107AID926; AID938
gemininHomo sapiens (human)Potency35.48130.004611.374133.4983AID624296
survival motor neuron protein isoform dHomo sapiens (human)Potency0.02240.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]